These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15268815)

  • 1. [The expression of PPAR gamma in experimental fatty liver disease].
    Zhao YC; Jiang LL; Li JM; Liang BL; Li L
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):437. PubMed ID: 15268815
    [No Abstract]   [Full Text] [Related]  

  • 2. [Expression of peroxisome proliferator-activated receptors Y changes with age in vascular smooth muscle cells of spontaneously hypertensive rat].
    Di ZL; Niu XL; Wei J; Li YQ; Chen GL; Wang NP
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):204-7. PubMed ID: 16608075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effects of glycine on the expression of peroxisome-proliferator-activated receptor gamma in nonalcoholic fatty rat livers].
    Liu JC; Guo YR; Chai B
    Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):702-3. PubMed ID: 18822216
    [No Abstract]   [Full Text] [Related]  

  • 4. Peroxisomal fatty acid metabolism, peroxisomal proliferator-activated receptors and non-alcoholic fatty liver disease.
    Macdonald GA; Prins JB
    J Gastroenterol Hepatol; 2004 Dec; 19(12):1335-7. PubMed ID: 15610304
    [No Abstract]   [Full Text] [Related]  

  • 5. Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac development of the rat.
    Steinmetz M; Quentin T; Poppe A; Paul T; Jux C
    Basic Res Cardiol; 2005 May; 100(3):263-9. PubMed ID: 15754086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between NF-kappa B binding activity and expression of PPAR gamma-mRNA in the livers of rats with fatty liver disease].
    Zhao CY; Wang JB; Deng ZJ; Liu JW; Li JM; Li L; Jiang LL
    Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):96-100. PubMed ID: 15727693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The association of Val227Ala polymorphism of the peroxisome proliferator activated receptor alpha (PPAR alpha) gene with non-alcoholic fatty liver disease].
    Chen SH; Li YM; Yu CH; Jiang LL
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jan; 15(1):64-5. PubMed ID: 17244467
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of medium- and long-chain fatty acid diets on PPAR and SREBP-1 expression and glucose homeostasis in ACBP-overexpressing transgenic rats.
    Oikari S; Ahtialansaari T; Huotari A; Kiehne K; Fölsch UR; Wolffram S; Jänne J; Alhonen L; Herzig KH
    Acta Physiol (Oxf); 2008 Sep; 194(1):57-65. PubMed ID: 18394026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Peroxisome proliferator-activated receptor in liver diseases].
    Zhao CY; Jiang LL
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jun; 11(6):382-4. PubMed ID: 12837233
    [No Abstract]   [Full Text] [Related]  

  • 10. Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats.
    Sun L; Ke Y; Zhu CY; Tang N; Tian DK; Gao YH; Zheng JP; Bian K
    Chin Med J (Engl); 2008 Nov; 121(22):2305-11. PubMed ID: 19080338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.
    de Gottardi A; Pazienza V; Pugnale P; Bruttin F; Rubbia-Brandt L; Juge-Aubry CE; Meier CA; Hadengue A; Negro F
    Aliment Pharmacol Ther; 2006 Jan; 23(1):107-14. PubMed ID: 16393287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
    Achanzar WE; Moyer CF; Marthaler LT; Gullo R; Chen SJ; French MH; Watson LM; Rhodes JW; Kozlosky JC; White MR; Foster WR; Burgun JJ; Car BD; Cosma GN; Dominick MA
    Toxicol Appl Pharmacol; 2007 Sep; 223(3):246-56. PubMed ID: 17663016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
    Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
    J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
    Nakamuta M; Kohjima M; Morizono S; Kotoh K; Yoshimoto T; Miyagi I; Enjoji M
    Int J Mol Med; 2005 Oct; 16(4):631-5. PubMed ID: 16142397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver.
    Romics L; Kodys K; Dolganiuc A; Graham L; Velayudham A; Mandrekar P; Szabo G
    Hepatology; 2004 Aug; 40(2):376-85. PubMed ID: 15368442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists.
    Fuster G; Busquets S; Ametller E; Olivan M; Almendro V; de Oliveira CC; Figueras M; López-Soriano FJ; Argilés JM
    Cancer Res; 2007 Jul; 67(13):6512-9. PubMed ID: 17616713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure.
    Mori Y; Hirano T; Nagashima M; Shiraishi Y; Fukui T; Adachi M
    Metabolism; 2007 Dec; 56(12):1714-8. PubMed ID: 17998026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of peroxisome proliferator activated receptor alpha in the pathogenesis of nonalcoholic steatohepatitis].
    Zhao CY; Deng ZJ; Zhou JY
    Zhonghua Gan Zang Bing Za Zhi; 2006 Feb; 14(2):146-7. PubMed ID: 16494792
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapy for nonalcoholic fatty liver disease.
    Moseley RH
    J Clin Gastroenterol; 2008 Apr; 42(4):332-5. PubMed ID: 18277910
    [No Abstract]   [Full Text] [Related]  

  • 20. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD.
    Bassaganya-Riera J; Hontecillas R
    Clin Nutr; 2006 Jun; 25(3):454-65. PubMed ID: 16698153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.